Generic substitution of levetiracetam resulting in increased incidence of breakthrough seizures

Annals of Pharmacotherapy

Volumn 45, Issue 5, 2011, Pages

  Fitzgerald, Christine L ^a   Jacobson, Mercedes P ^b  

^a TEMPLE UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiepileptic drug; Generic; Levetiracetam; Switch

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; PHENYTOIN; PREGABALIN; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ADULT; AGED; ANTICONVULSANT THERAPY; ARTICLE; BRAIN DISEASE; CASE REPORT; COMPLEX PARTIAL SEIZURE; DISEASE CONTROL; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GRAND MAL SEIZURE; HOSPITALIZATION; HUMAN; MALE; NARANJO SCORE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TONIC CLONIC SEIZURE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VAGUS NERVE STIMULATION;

ADULT; AGED, 80 AND OVER; ANTICONVULSANTS; DRUG SUBSTITUTION; DRUGS, GENERIC; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PIRACETAM; SEIZURES; TREATMENT FAILURE; YOUNG ADULT;

EID: 79957565853     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P765     Document Type: Article

References (22)

1. Duh MS, Cahill KE, Paradis PE, Cremieux PY, Greenberg PE. The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence. Expert Opin Pharmacother 2009;10:2317-28. DOI 10.1517/14656560903140525
2. Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 2007;48:464-9.DOI 10.111/j.1528-1167.2007.01007.x
3. LeLorier J, Duh MS, Paradis PE, et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 2008; 70:2179-86.DOI 10.1212/01.wnl.0000313154.55518.25
4. Duh MS, Paradis PE, Latremouille-Viau D, et al. The risks and costs of multiple-generic substitution of topiramate. Neurology 2009;72:2122-9.DOI 10.1212/wnl.0b013e3181aa5300
5. Labiner DM, Paradis PE, Manjunath R, et al. Generic antiepileptic drugs and associated medical resources utilization in the United States. Neurology 2010;74:1566-1574. DOI 10.1212/WNL.0b013e3181df091b
6. US Department of Health and Human Service, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Science, Office of Generic Drugs. Approved drug products with therapeutic equivalence evaluations (Orange Book). 2010. 30th ed. www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/UCM071436.pdf (accessed 2009 Oct 30).
7. Nightingale SL. Therapeutic equivalence of generic drugs-letter to health practitioners. 1998. www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm073182.htm. (accessed 2009 Oct 30).
8. Gidal BE. Bioequivalence of antiepileptic drugs: how close is close enough? Curr Neurol Neurosci Rep 2009;9:333-7.
9. Privitera MD. Generic antiepileptic drugs: current controversies and future directions. Epilepsy Curr 2008;8:113-7. DOI 10.1111/j.1535-7511.2008.00261.x
10. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
11. Product Information. Keppra (levetiracetam). Smyrna, GA: UCB, Inc., June 2008.
12. Rascati KL, Richards KM, Johnsrud MT, Mann TA. Effects of antiepileptic drug substitutions on epileptic events requiring acute care. Pharmacotherapy 2009;29:769-74. DOI 10.1592/phco.29.7.769
13. Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 2008;71:525-30.DOI 10.1212./01.wnl.0000319958.37502.8e
14. Zachry WM, Doan QD, Clewell JD, Smith BJ. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia 2009;50:493-500.DOI 10.1111/j.1528-1167.2008.01703.x
15. Berg MJ, Gross RA, Haskins LS, Zingaro WM, Tomaszewski KJ. Generic substitution in the treatment of epilepsy: patient and physician perceptions. Epilepsy Behav 2008;13:693-9. DOI 10.1016/j.yebeh.2008.06.001
16. McAuley JW, Chen AY, Elliott JO, Shneker BF. An assessment of patient and pharmacist knowledge of and the attitudes toward reporting adverse drug events due to formulation switching in patients with epilepsy. Epilepsy Behav 2009;14:113-7. DOI 10.1016/j.yebeh.2008.08.009
17. Makus KG, McCormick J. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. Clin Ther 2007;29:334-341.DOI 10.1016/j.clinthera.2007.02.005
18. Di Bonaventura C, Fattouch J, Fabbrini G, Manfredi M, Prencipe M, Giallonardo TA. Switching from branded to generic antiepileptic drugs as a confounding factor and unpredictable diagnostic pitfall in epilepsy management. Epileptic Disord 2007;9:465-6.
19. Welty TE, Pickering PR, Hale BC, Arazi R. Loss of seizure control associated with generic substitution of carbamazepine. Ann Pharmacother 1992;26:775-7.
20. Liow K, Barkley GL, Pollard JR, Harden CL, Bazil CW. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology 2007;68:1249-50.DOI 10.1212/01.wnl.000258400.30539.cc
21. American Epilepsy Society. The substitution of different formulations of antiepileptic drugs for the treatment of epilepsy. November 29, 2007. http://www.aesnet.org/index.cfm?objectid=77B16A48-E7FF-0F41-218E9CB3E54919D4 (accessed 2010 Apr 1).
22. US Department of Health and Human Service, Food and Drug Administration. MedWatch, the FDA safety information and adverse event reporting program. http://www.fda.gov/Safety/MedWatch/HowToReport/default.htm (accessed 2010 Jun 15).